GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TYK Medicines Inc (HKSE:02410) » Definitions » Cyclically Adjusted PB Ratio

TYK Medicines (HKSE:02410) Cyclically Adjusted PB Ratio : (As of Jun. 04, 2025)


View and export this data going back to 2024. Start your Free Trial

What is TYK Medicines Cyclically Adjusted PB Ratio?

TYK Medicines does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.

Shiller PE for Stocks: The True Measure of Stock Valuation


TYK Medicines Cyclically Adjusted PB Ratio Historical Data

The historical data trend for TYK Medicines's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TYK Medicines Cyclically Adjusted PB Ratio Chart

TYK Medicines Annual Data
Trend Dec22 Dec23 Dec24
Cyclically Adjusted PB Ratio
- - -

TYK Medicines Quarterly Data
Dec22 Mar23 Jun23 Dec23 Mar24 Jun24 Dec24
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial - - - - -

Competitive Comparison of TYK Medicines's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, TYK Medicines's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


TYK Medicines's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TYK Medicines's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where TYK Medicines's Cyclically Adjusted PB Ratio falls into.


;
;

TYK Medicines Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

TYK Medicines does not have a history long enough to calculate Cyclically Adjusted Book per Share. Therefore GuruFocus does not calculate Cyclically Adjusted PB Ratio for this company.


TYK Medicines  (HKSE:02410) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


TYK Medicines Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of TYK Medicines's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


TYK Medicines Business Description

Traded in Other Exchanges
N/A
Address
No.277 Longlan Road, 8th Floor, Building T2, China Eastern Binjiang Center, Xuhui District, Shanghai, CHN
TYK Medicines Inc is a clinical-stage biopharmaceutical company. The company is engaged in drug discovery research and development. The company and its subsidiaries are principally engaged in the research, development, and commercialization of pharmaceutical products. The company has built a pipeline with 12 drug candidates, including Core Product TY-9591, seven products in the clinical stage, and four products in the preclinical stage or early clinical development stage.
Executives
Nan Jing Yi Da Tou Zi Guan Li You Xian Gong Si
Nan Jing Yi Da Zi Ben Guan Li Qi Ye You Xian He Huo
Jiang Su Yi Da Gu Quan Tou Zi Ji Jin Guan Li You Xian Gong Si
Wu Yusheng 2201 Interest of corporation controlled by you
Zhu Julia Ming 2202 Interest of your spouse
Zheng Zhou Tai Ji Hong Nuo Yi Yao Gu Fen You Xian Gong Si 2101 Beneficial owner
Zhang Xing Li Yuan Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
He Chao 2201 Interest of corporation controlled by you
Bei Jing Hou Ji Jing Qiao Chuang Ye Tou Zi You Xian Gong Si 2201 Interest of corporation controlled by you
Bei Jing Rong Chen Hou Ji Tou Zi Guan Li You Xian Gong Si 2201 Interest of corporation controlled by you
Zhang Xing Xing Zhang Chan Ye Tou Zi He Huo Qi Ye You Xian He Huo 2101 Beneficial owner

TYK Medicines Headlines

No Headlines